Jun 26, 2026
Cosmo Pharmaceuticals reported positive 12-month Phase III data for Clascoterone 5% topical solution in male androgenetic alopecia, showing sustained hair growth and a safety profile comparable to vehicle. A separate metabolomics study characterized key inflammatory markers in scalp seborrheic dermatitis, identifying Malassezia fungi and specific free fatty acids as central drivers of the condition.
Apr 27, 2026
Veradermics will host an April 27, 2026 investor call to review topline results from Part A of its Phase 2/3 '302' trial of VDPHL01 in males with pattern hair loss. VDPHL01 is an investigational extended-release oral minoxidil tablet in Phase 3 development.
Mar 13, 2026
Recent studies examine safety profiles of GLP-1 receptor agonists, finding increased risk for nonscarring hair loss but improved survival in patients with brain metastases and type 2 diabetes.
Mar 10, 2026
Pharmaceutical companies are developing innovative hair loss treatments that directly activate hair growth pathways rather than suppressing male hormones, with several candidates entering clinical trials and promising enhanced safety profiles.
Feb 19, 2026
KilgourMD announced phase II clinical trial results showing 53% of menopausal women with hair loss achieved meaningful regrowth within four months, with a 60% reduction in hair shedding.
